Tumor PD-L1 induces β2m ubiquitylation and degradation for cancer cell immune evasion

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Immune checkpoint blockade therapy targeting PD-1/PD-L1 is a promising cancer treatment.
• Resistance to anti-PD-1/PD-L1 therapy remains a significant clinical challenge.
• Existing resistance mechanisms primarily focus on external factors, not PD-L1 itself.

Purpose of the Study:

• To investigate novel, intrinsic mechanisms of resistance to anti-PD-1/PD-L1 immunotherapy.
• To elucidate the role of PD-L1 beyond its canonical immune-inhibitory function.
• To identify new therapeutic strategies to overcome resistance.

Main Methods:

• Investigated the enzymatic activity of PD-L1.
• Utilized ubiquitylation assays to study PD-L1's interaction with β2m.
• Assessed MHC-I surface levels on tumor and antigen-presenting cells.
• Evaluated the impact of disrupting PD-L1's ligase activity on immunotherapy response in preclinical models.

Main Results:

• Discovered that PD-L1 possesses E3 ubiquitin ligase activity.
• PD-L1 directly ubiquitinates β2m, leading to its degradation.
• This degradation reduces surface MHC-I levels on tumor cells and antigen-presenting cells.
• Reduced MHC-I impairs CD8+ T cell recognition, contributing to immunotherapy resistance, especially in low β2m tumors.
• Inhibiting PD-L1's ligase activity or PD-L1-β2m interaction enhances sensitivity to PD-L1 blockade therapy.

Conclusions:

• PD-L1 has an intrinsic E3 ubiquitin ligase function crucial for immune evasion.
• This newly identified mechanism contributes to intrinsic resistance to anti-PD-1/PD-L1 therapy.
• Targeting PD-L1's ligase activity represents a potential strategy to improve immunotherapy efficacy.